Skip to content

STAAR Surgical Company (STAA) Company Overview

Company Analysis

STAAR Surgical Company STAA

A comprehensive view of key metrics, scores, and financial health for STAAR Surgical Company

Overview of STAAR Surgical Company

STAA NGM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Small Cap
STAAR Surgical Company (STAA), is a Small Cap company, in the Medical Instruments & Supplies industry, last closed at $24.94, about 78.1% overvalued vs fair value, -6.3% 1Y return, placing in the top 25% of its sector.
Metrics Rev Growth -23.7% ROE -21.7% Gross Margin 76.2%
USD 24.94
1.63%
(Delayed)
• Vol 90d: 51.4%
52-Week Range
Market Cap
$1.25B
Enterprise Value
$1.10B
Overall Score
Overall
Growth
Good
Profitability
Good
Health
Weak
Efficiency
Good
Valuation
Fair
Growth
Good
Profitability
Good
Health
Weak
Efficiency
Good
Valuation
Fair
Completeness: 82%
Confidence: 91%
Updated: Oct 31
Top Beats

Quick Facts

HQ Lake Forest, CA
Employees 1,157
Fiscal year Dec 31

Next Events

Earnings Nov 4 Call: Nov 4

Fair Value Snapshot

Bear Base Bull
$5
$5
$6
Current: $24.94 -78% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$239.4M
-23.7%%
Gross Profit
$182.4M
-23.9%%
Operating Income (GAAP)
-$91.7M
-627.2%%
EBITDA
-$37.2M
-550.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
76.2%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating STAAR Surgical Company's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
51
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.95). This signals strong consumable attach-rate economics.
  • Comfortable Interest Coverage Interest coverage quality is strong vs peers (score 0.85). Debt servicing capacity supports continued M&A optionality.

Key risks

  • Weak FCF Generation FCF margin quality lags peers (score 0.34). Below-peer FCF conversion is a MedTech quality warning.
  • Weak Capital Return Profile Capital return quality is below peers (score 0.34). Low ROIC raises questions about M&A discipline and pipeline ROI.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
92

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing STAA's balance between Growth (10.8%), Profitability (38.3%), and Safety (50.9%). Growth 11% Safety 51% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

14th percentile vs peers
15
Key Signals
Rev Growth YoY -23.7% 14p Revenue CAGR 3Y -5.6% 18p TSR -35.7% 22p Asset Growth YoY -11.3% 22p EPS Growth YoY -2.95 4p
  • Gross Profit Margin in top 20% of peers (76.2%, 85th percentile)
  • Interest Coverage (EBITDA) in top 20% of peers (19.73, 87th percentile)
  • Net Debt/EBITDA in top 20% of peers (-5.51, 87th percentile)
  • Equity/Assets in top 20% of peers (76.2%, 80th percentile)
  • Growth in bottom 20% of peers (percentile: 14)
  • Rev Growth YoY in bottom 20% of peers (-23.7%)
  • EPS Growth YoY in bottom 20% of peers (-2.95)

Profitability

51th percentile vs peers
52
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

69th percentile vs peers
69
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for STAAR Surgical Company.

Loading scenario defaults...
Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$5.45
- - -
-78.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000